Professional Documents
Culture Documents
Project Salus
Executive Summary
Project Salus Project Salus provides answers
to these questions
Basic questions which require ▪ VE of both mRNA vaccines appears to wane over
data-driven answers time in this large 5.6M US-based 65 & over vaccinated cohort
• Breakthrough case definition: new COVID-19 diagnosis (by COVID-19 ICD-10 code) occurring no earlier than
2-weeks post the second vaccine dose (see appendix for more details on case definition)
▪ COVID-19 case definition: COVID-19 ICD-10-CM code U071 found in any claim type. Date of diagnosis
based on first claim with U071. Note: 29% have either a COVID-19 PCR or antigen test in a claim.
▪ COVID-19 breakthrough infection definition: COVID-19 diagnosis more than 2 weeks after second dose
of mRNA vaccine or single dose of J&J vaccine with no COVID-19 ICD-10 code U071 between first and
second dose of mRNA vaccine. Note: 36% of breakthrough cases have either a COVID-19 PCR or antigen
test in a claim.
▪ COVID-19 hospitalization definitions: (1) Inpatient claim with primary admitting diagnosis ICD-10-C
code U071 with data of admission within 14 days after COVID-19 diagnosis or date of discharge within
10 days of post hospitalization COVID-19 diagnosis OR (2) Carrier claim with ICD10 code U071 and place
of service code = 21 and date of service either 14 days after COVID-19 diagnosis or 10 days before
COVID-19 diagnosis.
▪ COVID-19 associated death definitions: (1) Inpatient claim patient discharge status code = 41 (expired
in facility) OR (2) MBSF file Date of Death are within 60 days of COVID-19 diagnosis. 85% of COVID-19
deaths using this definition occurred within 30 days and 72% within 20 days of COVID-19 diagnosis
5
Key Breakthrough vs. Pre-Vaccination COVID-19 Metrics
Project Salus
Among 5.6M fully vaccine immunized Salus cohort members aged 65 and older
(2.7M Pfizer and 2.9M Moderna), as of September 10, 2021:
• 2.9% cumulative breakthrough rate
• 21% hospitalization rate in breakthrough infections, reduced three-fold from
32% hospitalization rate March – December 2020
• 31% breakthrough hospitalizations include ICU care, equivalent to
32% ICU rate March – December 2020
• 4.0% death rate in breakthrough infections, reduced three-fold from
12% death rate March – December 2020
6
Total & Breakthrough Cases in the 65 Years and Older Salus Cohort
Project Salus
Breakthrough cases =
71% of total Covid-19
cases in cohort
7
*CDC data: % of SARS-CoV-2 genomes sequenced
Is mRNA Vaccine Effectiveness Against Delta Breakthrough
Project Salus
Infection Waning Over Time in 65 Years and Older Salus Cohort?
☥
☥ Breakthrough infection rates 5-6
☥ ☥ months since vaccination > 3-4
☥ ☥ months since vaccination
P < 0.001
8
Age Distribution of Vaccinated Groups in the
Project Salus 65 Years and Older Cohort
▪ Could higher proportion of
85 years and older members
in first vaccinated group
explain reduced VE?
9
Does Age Affect Vaccine Effectiveness Against Breakthrough
Project Salus
Infections in the 65 Years and
-
Older Cohort?
• Age has a minor contribution
to the reduced vaccine
+
NS protection seen in the group
-
NS vaccinated 5-6 months ago
+ # #
NS
August 21 ++
July 31 98% **
July 10
June 19 96% #
82%
36%
Delta variant ++ #
+++ ***
***
#
+++ 95% CI
++
+ *** *** ++
** #
**
# # Over 85 > Over 85 > 75 to 84 >
# # 75 to 84 65 to 74 65 to 74
P < 0.001 +++ *** none
P > 0.05 - NS #
10
Are There Differences in Waning Effectiveness Between Pfizer-
Project Salus BioNTech and Moderna Vaccines in the 65 Years and Older Cohort ?
NS
▪ Waning immunity are seen with both
Pfizer-BioNTech and Moderna vaccines
during Delta phase of the pandemic
NS ▪ Moderna vaccine offers better
August 21 NS
protection than Pfizer vaccine for
July 31
July 10 96%
98%
NS
individuals vaccinated 4 months prior for
June 19
36%
82% weeks ending after July 31
Delta variant #
*
* 95% CI
NS
*
P < 0.05 ☩
P > 0.05 NS
11
Total & Breakthrough Hospitalizations in the
Project Salus 65 Years and Older Cohort
▪ As Delta variant surged to over 50%
in June, COVID-19 hospitalizations
more than doubled, reversing the
August 14
98% prior trend of decreasing
June 26
May 22 53% hospitalizations since April
4% Delta variant ▪ In this 80% vaccinated 65+
population, an estimated 60% of
COVID-19 hospitalizations occurred
in fully vaccinated individuals in the
week ending August 7th
60% of COVID-19
hospitalizations are in
vaccinated individuals
12
Is Vaccine Protection Against Breakthrough Hospitalization
Project Salus
Waning Over Time in the 65 Years and Older Cohort?
▪ VE against breakthrough
hospitalization is significantly
lower 5-6 months post
vaccination than 3-4 months
☥ ☥
post vaccination
August 7
July 10 96%
June 19 82%
36%
Delta variant
☥
☥
☥
☥
95% CI
☥
☥
☥ Breakthrough hospitalization rate for
5-6 months since vaccination > 3-4
months
P < 0.001
13
Are there Age Differences in Vaccine Protection Against
Project Salus
Breakthrough Hospitalizations in the 65 Years and Older Cohort?
+++ +++
***
*** ▪ Older age associated with
increased breakthrough
hospitalization rates
August 7
July 10 96%
June 19 82%
36% ++
Delta variant xxx #
***
++
*** 95% CI
+++ #
*** - Over 85 > Over 85 > 75 to 84 >
*** xx
- 75 to 84 65 to 74 65 to 74
*** xx
-
xx NS P < 0.001 +++ *** xxx
xx
#
P < 0.01 ++ none xx
P < 0.05 + none x
P > 0.05 - NS #
14
What is the Vaccine Effectiveness Against the Delta Variant in
Project Salus
the Salus Cohort? – Using the CDC Screening Approach
▪ 41% calculated VE against
infection
▪ VE of both mRNA vaccines in this 65+ cohort is lower than previously reported in smaller study sizes for both
COVID-19 infection and hospitalization
▪ VE for mRNA vaccines is higher against hospitalization than against infection
Graphic adapted from CDC Presentation ACIP Meeting August 30, 2021, Oliver, S. Framework for Booster Doses of COVID-19 Vaccines 16
Risk Model for Breakthrough Hospitalization
Project Salus
17